The goal of this renewal application is to define the largely unexplored relationship between the ATM/ATR/Chk1 DNA-damage checkpoint machinery and the Src/Ras/Raf/MEK/ERK survival signaling pathway in multiple myeloma (MM) cells, and to exploit this knowledge therapeutically. The previous project stemmed from the observation that the multi-kinase and Chk1 inhibitor UCN-01 triggered MEK/ERK activation in MM cells, and that pharmacologic interruption of this pathway strikingly induced apoptosis in malignant cells, including primary CD138+, but not normal cells. During the preceding period, important new insights emerged, including the observations that a) disruption of Chk1 by UCN-01 activates MEK1/2/ERK1/2 through a Ras- dependent mechanism that limits lethality;b) these findings may represent a generalized phenomenon involving novel and more specific Chk1 inhibitors as well as new agents acting upstream of Chk1 (i.e., ATM/ATR inhibitors);c) interrupting the MEK/ERK pathway at various levels, e.g., by new, clinically relevant MEK1/2 inhibitors as well as antagonists of upstream signaling targets (e.g., Src and Ras) dramatically potentiates checkpoint abrogator lethality;d) the lethality of these regimens is associated with marked potentiation of DNA damage and induction of Bim-dependent apoptosis;e) this approach is highly lethal toward non-cycling G0G1 MM cells and circumvents Mcl-1-related resistance;and e) this strategy is effective in vivo. Collectively, our findings argue that in MM, activation of the Ras/Raf/MEK/ERK pathway represents a critical cytoprotective response to Chk1/ATM/ATR inhibitors, and that blockade of the former pathway leads to pronounced activity against MM cells both in vitro and in vivo.
The specific aims of this proposal are to 1) validate, through genetic means, the Chk1 and MEK/ERK pathways as targets for regimens combining new generation Chk1 and ATM/ATR inhibitors with MEK/ERK pathway antagonists in MM, and investigate mechanisms responsible for synergistic interactions, focusing on Bim upregulation, DNA damage induction, and cdc2 activation;2) test the activity and selectivity of novel regimens toward primary CD138+ MM cells, and elucidate mechanisms responsible for the striking susceptibility of non-cycling G0G1 and primary MM cells to this strategy;3) define the basis by which these regimens circumvent cytoprotection by Mcl-1, a critical MM survival factor, and use genetic and pharmacologic strategies to determine whether disabling of Bcl-2/Bcl-xL improves therapeutic activity further;and 4) determine whether regimens combining second-generation Chk1 and ATM/ATR inhibitors with MEK/ERK pathway antagonists overcome conventional, novel (e.g., stromal-cell related), and bortezomib resistance, emphasizing in vivo flank and systemic xenograft MM model systems. These studies will establish a new treatment paradigm for Chk1 inhibitors and lay the foundation for one or more novel Phase I trials in refractory MM in which emerging inhibitors of the ATM/ATR/Chk1 checkpoint machinery and the MEK/ERK survival pathway are rationally combined to trigger MM cell death.

Public Health Relevance

Despite recent advances in the treatment of multiple myeloma, it largely remains an incurable disease, and new treatment options are urgently needed. The goal of this study is to develop an entirely novel therapeutic strategy for the treatment of this disorder involving agents that interrupt DNA damage checkpoints and an important survival signaling pathway. If successful, these studies could lead to the development of a more effective therapy for patients with refractory multiple myeloma and potentially other blood cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA100866-08
Application #
8259194
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Arya, Suresh
Project Start
2003-05-01
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
8
Fiscal Year
2012
Total Cost
$242,485
Indirect Cost
$80,288
Name
Virginia Commonwealth University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Chen, Shuang; Zhang, Yu; Zhou, Liang et al. (2014) A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 124:2687-97
Bose, Prithviraj; Dai, Yun; Grant, Steven (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143:323-36
Rahmani, Mohamed; Aust, Mandy Mayo; Benson, Elisa C et al. (2014) PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res 20:4849-60
Chen, Shuang; Zhou, Liang; Zhang, Yu et al. (2014) Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Mol Cell Biol 34:3435-49
Nguyen, Tri K; Grant, Steven (2014) Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol Cancer Ther 13:662-74
Vachhani, Pankit; Bose, Prithviraj; Rahmani, Mohamed et al. (2014) Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiol Genomics 46:448-56
Pei, Xin-Yan; Dai, Yun; Felthousen, Jessica et al. (2014) Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. PLoS One 9:e89064
Bose, Prithviraj; Grant, Steven (2014) Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res 38:862-5
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Dasmahapatra, Girija; Patel, Hiral; Friedberg, Johnathan et al. (2014) In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Mol Cancer Ther 13:2886-97

Showing the most recent 10 out of 100 publications